1
|
Singh M, Malhotra L, Haque MA, Kumar M, Tikhomirov A, Litvinova V, Korolev AM, Ethayathulla AS, Das U, Shchekotikhin AE, Kaur P. Heteroarene-fused anthraquinone derivatives as potential modulators for human aurora kinase B. Biochimie 2021; 182:152-165. [PMID: 33417980 DOI: 10.1016/j.biochi.2020.12.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 12/10/2020] [Accepted: 12/29/2020] [Indexed: 01/30/2023]
Abstract
The quest for effective anticancer therapeutics continues to be extensively pursued. Over the past century, several drugs have been developed, however, a majority of these drugs have a poor therapeutic index and increased toxicity profile. Hence, there still exists ample opportunity to discover safe and effective anticancer drugs. Aurora Kinase B (AurB), a member of the Aurora kinase family and a key regulator of mitotic cell division, is found to be frequently overexpressed in a variety of human cancers and has thus emerged as an attractive target for the design of anticancer therapeutics. In the present study, a structure-based scaffold hopping approach was utilized to modify the heterocyclic moiety of (S)-3-(3-aminopyrrolidine-1-carbonyl)-4,11-dihydroxy-2-methylanthra [2,3-b]furan-5,10-dione (anthrafuran 1) to generate a series of heteroarene-fused anthraquinone derivatives, which were then subjected to virtual screening for the identification of potential AurB inhibitors. The obtained hits were subsequently synthesized and evaluated by using a combination of in silico and biophysical techniques for elucidating their in vitro binding and inhibition activity with recombinantly expressed AurB. Four identified hits presented an improved binding profile as compared to their parent analog anthrafuran 1. One derivative, anthrathiophene 2 demonstrated excellent in vitro inhibition of AurB (7.3 μM).
Collapse
Affiliation(s)
- Mandeep Singh
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India
| | - Lakshay Malhotra
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India
| | - Md Anzarul Haque
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India
| | - Mukesh Kumar
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India
| | - Alexander Tikhomirov
- Gause Institute of New Antibiotics, Moscow, 11 B. Pirogovskaya Street, Moscow, 119021, Russia
| | - Valeria Litvinova
- Gause Institute of New Antibiotics, Moscow, 11 B. Pirogovskaya Street, Moscow, 119021, Russia
| | - Alexander M Korolev
- Gause Institute of New Antibiotics, Moscow, 11 B. Pirogovskaya Street, Moscow, 119021, Russia
| | - A S Ethayathulla
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India
| | - Uddipan Das
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India
| | - Andrey E Shchekotikhin
- Gause Institute of New Antibiotics, Moscow, 11 B. Pirogovskaya Street, Moscow, 119021, Russia
| | - Punit Kaur
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India.
| |
Collapse
|
2
|
Three-component condensation of 2,4-diaminothiazoles with aldehydes and Meldrum’s acid. The synthesis of 7-aryl- and 7-alkyl-6,7-dihydro-4H-thiazolo[4,5-b]pyridin-5-ones. Russ Chem Bull 2009. [DOI: 10.1007/s11172-008-0230-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Three-component condensation of 2,4-diaminothiazoles with aldehydes and Meldrum's acid: synthesis of 7-aryl(alkyl)-substituted 6,7-dihydro-4H-thiazolo[4,5-b]pyridin-5-ones. MENDELEEV COMMUNICATIONS 2009. [DOI: 10.1016/j.mencom.2009.03.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
5
|
Wang HY, Cao ZX, Li LL, Jiang PD, Zhao YL, Luo SD, Yang L, Wei YQ, Yang SY. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors. Bioorg Med Chem Lett 2008; 18:4972-7. [PMID: 18762425 DOI: 10.1016/j.bmcl.2008.08.033] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2008] [Revised: 07/24/2008] [Accepted: 08/09/2008] [Indexed: 02/06/2023]
Abstract
Pharmacophore models of Polo-like kinase-1 (PLK1) inhibitors have been established by using the HipHop and HypoGen algorithms implemented in the Catalyst software package. The best quantitative pharmacophore model, Hypo1, which has the highest correlation coefficient (0.9895), consists of one hydrogen bond acceptor, one hydrogen bond donor, one hydrophobic feature, and one hydrophobic aliphatic feature. Hypo1 was further validated by test set and cross validation method. Then Hypo1 was used as a 3D query to screen several databases including Specs, NCI, Maybridge, and Chinese Nature Product Database (CNPD). The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking study to refine the retrieved hits and as a result to reduce the rate of false positive. Finally, a total of 20 compounds were selected and have been shifted to in vitro and in vivo studies. As far as we know, this is the first report on the pharmacophore modeling even the first publicly reported virtual screening study of PLK1 inhibitors.
Collapse
Affiliation(s)
- Hui-Yuan Wang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Keyuan Road 4, Chengdu, Sichuan 610041, China
| | | | | | | | | | | | | | | | | |
Collapse
|